← Return to Promising news on targeting KRAS G12D mutations

Discussion

Promising news on targeting KRAS G12D mutations

Pancreatic Cancer | Last Active: Mar 23 11:08pm | Replies (4)
Comment receiving replies
@sdd3460

You provide such a wealth of information and positive encouragement. Thank you!

I have recently learned that KRAS p.Q61H mutation is what my family is dealing with. From what I can tell it is a relatively rare one.

Anyone have any experience or insight they’d like to share?

Jump to this post

Replies to "You provide such a wealth of information and positive encouragement. Thank you! I have recently learned..."
stageivsurvivor | @stageivsurvivor | Mar 23 11:08pm

For the KRAS Q61 mutation, there is a “pan” KRAS trial using the drug compound RMC-6236 that interrupts the cell signaling pathway upstream from where the KRAS variants occur.

RMC-6236 binds to the RAS molecule which serves as an “off switch” to stop cell growth and proliferation. By having the RNC-6236 bind to RAS, the “switch is turned from ON (unchecked growth and proliferation) to OFF. Occurring upstream of the KRAS Q61 location, the cell signaling pathway is interrupted initiating apoptosis (programmed cell death).

This trial is recruiting at multiple locations in the US and can be found on clinical trials.gov or calling the Pancreatic Cancer Action Network at 877.272.6226, M-F, 7:00am-5:00pm PT.

VIEW AND REPLY